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Abstract
Background: Cardiomyopathies are a rare cause of pediatric heart disease, but they are one of 
the leading causes of heart failure admissions, sudden death, and need for heart transplant in 
childhood. Reports from the Pediatric Cardiomyopathy Registry (PCMR) have shown that almost 
40% of children presenting with symptomatic cardiomyopathy either die or undergo heart 
transplant within 2 years of presentation. Little is known regarding circulating biomarkers as 
predictors of outcome in pediatric cardiomyopathy.
Study Design: The Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) study 
is a multi-center prospective study conducted by the PCMR investigators to identify serum 
biomarkers for predicting outcome in children with dilated cardiomyopathy (DCM) and 
hypertrophic cardiomyopathy (HCM). Patients less than 21 years of age with either DCM or HCM 
were eligible. Those with DCM were enrolled into cohorts based on time from cardiomyopathy 
diagnosis: categorized as new onset or chronic. Clinical endpoints included sudden death and 
progressive heart failure.
Results: There were 288 children diagnosed at a mean age of 7.2±6.3 years who enrolled in the 
PCM Biomarkers Study at a median time from diagnosis to enrollment of 1.9 years. There were 80 
children enrolled in the new onset DCM cohort, defined as diagnosis at or 12 months prior to 
enrollment. The median age at diagnosis for the new onset DCM was 1.7 years and median time 
from diagnosis to enrollment was 0.1 years. There were 141 children enrolled with either chronic 
DCM or chronic HCM, defined as children ≥2 years from diagnosis to enrollment. Among 
children with chronic cardiomyopathy, median age at diagnosis was 3.4 years and median time 
from diagnosis to enrollment was 4.8 years.
Conclusion: The PCM Biomarkers study is evaluating the predictive value of serum biomarkers 
to aid in the prognosis and management of children with DCM and HCM. The results will provide 
valuable information where data are lacking in children.
Clinical Trial Registration: NCT01873976—https://clinicaltrials.gov/ct2/show/
NCT01873976?term=PCM+Biomarker&rank=1
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Cardiomyopathies are a rare cause of heart disease worldwide and across all age groups 
when compared to ischemic heart disease, but they are one of the leading causes of heart 
failure (HF) admissions, sudden death, and need for heart transplant in childhood.1-3 Reports 
from the Pediatric Cardiomyopathy Registry (PCMR) have shown that almost 40% of 
children presenting with symptomatic cardiomyopathy either die or undergo heart transplant 
within 2 years of presentation.2,4,5 However, symptoms and even echocardiographic 
abnormalities do resolve in many children with cardiomyopathy over months to years after 
initial presentation.6,7
Large registry and cohort studies in children with cardiomyopathy have focused primarily on 
echocardiographic characteristics of cardiac function at the time of diagnosis as predictors of 
outcome.4,7-13 The North American PCMR and Cohort study collected demographic, 
clinical, electrocardiographic and Holter monitor data, and echocardiographic measures on 
more than 3500 children across the United States and Canada.14 The National Australian 
Childhood Cardiomyopathy Study, another large cohort of patients with pediatric 
cardiomyopathy, also collected clinical information and echocardiographic characteristics 
related to the causes and outcomes of cardiomyopathy in children.15 The data collected from 
these studies provide valuable information pertaining to the presentation, clinical course, and 
predictors of outcomes of childhood cardiomyopathy. To date, the predictors of outcomes 
including clinical phenotype at presentation as well as predictive surrogate endpoints such as 
biomarkers, have not been prospectively validated in childhood cardiomyopathy.
Study Rationale
Interest and knowledge continue to increase in the study of serum biomarkers of early heart 
disease in adults with cardiomyopathy and HF; in predicting hospital readmission for HF, 
mortality, and need for heart transplant; and as surrogate endpoints for clinical trials in 
adults.16-18 However, similar large-scale studies have not been performed in children with 
cardiomyopathy. Given this lack of data, we designed a multi-center prospective study to 
identify which serum biomarkers or biomarker panels might be sensitive and specific enough 
to identify disease severity status in pediatric cardiomyopathy, including asymptomatic 
disease, acute HF, chronic and stable HF, and progressive HF resulting in mechanical 
circulatory support, heart transplant, or sudden cardiac death.
Here, we describe the design, implementation, and preliminary results of the National Heart, 
Lung, and Blood Institute (NHLBI)-funded Cardiac Biomarkers in Pediatric 
Cardiomyopathy (PCM Biomarkers) study. The authors are solely responsible for the design 




The PCM Biomarkers study was funded by the NHLBI from August 6, 2012, through June 
30, 2017. The study used the network of clinical investigators and infrastructure established 
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by the NHLBI-funded PCMR (funded from 1995 through 2012).14,19 The primary award 
sites for this study were the University of Miami (2012 to 2014) and Wayne State University 
(2014 to 2017), which served as the Administrative Coordinating Center (ACC) (Figure 1). 
The ACC was responsible for implementing the study, overall regulatory and clinical 
compliance, protocol implementation and support, management and oversight of the core 
facilities that store the study biospecimens, echocardiograms and cardiac magnetic 
resonance imaging studies (cMRI).
The ACC served as the central storage facility for the biospecimens. The University of 
Miami served as the central laboratory responsible for the biomarker assays. Boston 
Children’s Hospital served as the core laboratory for centralized review and measurement of 
all echocardiograms. Washington University in St. Louis, MO served as the core laboratory 
for centralized review and measurement of all cMRI.
In addition, the ACC managed and directed the manuscript-writing groups, coordinating 
activities among centers, the data collection at the participating clinical centers (Appendix 
A), and the study analysis planning through continued conferencing with the Steering 
Committee Investigators. The ACC also coordinated with The New England Research 
Institutes (NERI), which served as the Data and Statistical Coordinating Center (DCC) for 
managing data, conduct of statistical analyses, developing data collection forms, and 
preparing the study’s operations manual and reports for the Observational Study Monitoring 
Board (OSMB), Figure 1.
Study Design
The PCM Biomarkers study was designed to be a 4-year prospective study of up to 480 
children with either primary dilated cardiomyopathy (DCM) or hypertrophic 
cardiomyopathy (HCM). The study had three components: 1) clinical data collection by 
chart review; 2) biospecimen collection and testing; and 3) centralized review and 
measurement of echocardiograms and cMRI. The protocols used to acquire 
echocardiographic studies and cMRI studies are detailed in Appendices B and C, 
respectively.
The study consisted of two specific aims for DCM, two specific aims for HCM phenotypes, 
along with a third specific aim for both phenotypes. There were two DCM cohorts based on 
the acuteness of illness. The first was comprised of children who were recently diagnosed 
(diagnosed at enrollment or up to 12 months prior to enrollment). The purpose in studying 
children with DCM diagnosed between 0 and 12 months prior to enrollment was to 
determine the ability of serum cardiac biomarkers to predict the short-term (<90 days) and 
intermediate-term (≥90 days) clinical outcomes children soon after a diagnosis of DCM. The 
study was designed to analyze the ability of either the concentrations of biomarkers at acute 
presentation or the change in concentrations over time to correlate with outcome. Serial 
biospecimens, echocardiograms, and clinical data were obtained at as many of the following 
time points as possible based on clinically indicated testing: at diagnosis and months 1, 3, 6, 
12, and 24. Additionally, the study was designed to determine whether a single biomarker or 
a biomarker panel predicted poor outcomes (death, heart transplant, or worsening HF) in the 
first 2 years after diagnosis of DCM.
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The second DCM cohort was comprised of children with clinically stable DCM, defined as 
children surviving at least 1 year after the initial diagnosis of cardiomyopathy without heart 
transplant and without an anticipated need for heart transplant within 12 months of 
enrollment. In this group, biospecimens were collected at time of enrollment and at 12 and 
24 months after enrollment. The objective was to determine whether there was any 
association between the circulating biomarkers and symptoms, echocardiographic findings, 
or disease progression in children with clinically stable DCM.
With respect to HCM, we assessed the clinical utility of biomarkers of collagen metabolism 
in children with HCM (at any time point in their disease course) and investigated serial 
biomarkers in a cohort of clinically stable HCM patients (at least 1 year from initial 
presentation of HCM). We collected blood samples in proximity to cMRI and 
echocardiographic assessments. The study was designed to evaluate the relationship between 
biomarker concentrations and non-invasive imaging evidence of fibrosis as detected by 
delayed enhancement on cMRI or left ventricular (LV) diastolic dysfunction by 
echocardiography. The study was also planned to determine the agreement between 
echocardiographic and cMRI measurements of septal hypertrophy and LV mass by 
analyzing imaging studies acquired within 6 months of each other. In the clinically stable 
HCM cohort, biospecimens were obtained at the same time points as the clinically stable 
DCM cohort to identify an association between biomarkers and symptoms, 
echocardiographic findings, and disease progression in children with chronic HCM.
There were several biomarkers hypothesized to relate to cause and disease state (Table 1). 
These included biomarkers thought to relate to the possible cause of DCM and to acute 
changes in clinical condition soon after diagnosis. In addition, biomarkers of myocardial 
fibrosis were obtained in children with HCM to assess for a correlation between fibrosis 
apparent by cMRI. Biomarkers were also obtained in children with HCM to determine a 
biomarker profile in children with echocardiographic evidence of marked hypertrophy or 
diastolic dysfunction. Biomarkers thought to be associated with a clinical worsening of HF 
in either DCM or HCM were analyzed in the clinically stable patients to determine the 
profile of these biomarkers in children felt to be at low risk for clinical event.
Patient Selection
Patient eligibility was based on a cardiomyopathy diagnosis that met strict 
echocardiographic criteria. These criteria have been consistent with prior PCMR studies 
with the exception of one of the HCM criteria.19 For DCM, children eligible must have both 
decreased LV function and dilation as a means of excluding those with acute fulminant 
myocarditis and excluding those who have normal function but LV dilation for other reasons 
such as bradycardia or anemia. In children, an absolute septal thickness has not been used 
for the diagnosis of HCM, particularly because the measurements need to be interpreted in 
the context of the size of the child. An LV posterior wall or septal thickness at end-diastole 
Z-score of 4-6 standard deviations above the normal mean for body-surface area has been 
suggested as possible HCM and a Z-score of 7 or more as definite HCM in children.20 In the 
prior PCMR studies, a posterior wall thickness of >2 standard deviations above the normal 
mean for body-surface area was used as an inclusion criteria.19 For the current study, the 
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investigators were more selective requiring an LV posterior wall or septal thickness Z-score 
>3 to meet HCM inclusion criteria (certainly above the normal range for most children) 
(Table 2). Patients less than 21 years old at enrollment and alive without heart transplant at 
the time of enrollment were eligible. The date of cardiomyopathy diagnosis was the date of 
the earliest available echocardiogram, cMRI, or imaging report that confirmed the diagnosis 
of cardiomyopathy based on the criteria in Table 2. This date of diagnosis was then used to 
determine eligibility for enrollment into the appropriate study cohorts. Children with 
secondary causes of cardiomyopathy and cardiomyopathy associated with syndromic, 
metabolic, or storage disease were excluded (Table 3).
Data Collection
The study used the network of clinical centers and infrastructure established by the NHLBI-
funded PCMR to estimate site-specific enrollment based on historic incidence and 
prevalence of childhood cardiomyopathy, to orient the investigators who were familiar with 
PCMR enrollment criteria and data collection, and to efficiently identify eligible patients.
The local coordinator at participating sites completed the electronic eligibility and 
enrollment forms. Data were entered into the eCOS web-based system, which was 
developed and maintained by the DCC. The web-based electronic data management system 
provided reliable and secure data entry by allowing study staff and investigators to enter and 
access data through the Internet using a standard browser. This system provided real-time, 
field-level validation, paperless data collection, automatic query management, and tracking 
of laboratory specimens and test results. Standardized reports were sent monthly to the ACC 
regarding enrollment, specimen status, and reimbursement for sites and core laboratories. 
Several levels of security ensured the privacy and integrity of study data. The database server 
allowed for archiving and backup, as well as an audit trail to identify user, date and time, and 
old and new values for data that were entered or changed.
All patient identifiers were removed from the data sent to the DCC. As per current NIH 
requirements, specific data were collected such that enrolled subjects were assigned a 
globally unique identifier to be used for this and future studies in which the subject might be 
enrolled.21 To facilitate timely, complete, and standardized data extraction, an outreach team 
of full-time data collectors who traveled to participating sites to collect relevant clinical data 
at regular intervals was established and based at the ACC. There was an Observational Study 
Monitoring Board that reviewed the operations and data collection semiannually with the 
ACC and DCC.
Biospecimen and Image Collection and Processing
Blood was drawn either at the time of clinically indicated blood draws or at the discretion of 
the site study coordinator. No more than 5 mL per 5 pounds of body weight, up to a 
maximum of 21.5 mL, were obtained from each patient at each sample collection. Samples 
were sent by express mail to the Study Biological Specimen Repository and logged in the 
DCC database. Blood samples were processed centrally and in batches at the Clinical 
Laboratory Improvement Amendments-certified Immunoassay and Chemistry Core 
Laboratory.
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Trained sonographers at each site acquired echocardiograms for clinical purposes, as per the 
protocol (Appendix A) for obtaining images. The images were de-identified and sent via AG 
MedNet software to the Core Echocardiography Laboratory for central measurement. Each 
echocardiogram was assigned a unique identification number provided by the DCC. The 
new identification number was independent of the subject identification number and blinded 
the core laboratory to the study visit. Likewise, the cMRI images were for clinical purposes, 
as per the cMRI protocol (Appendix B). Images were de-identified, sent via a File Transfer 
Protocol system to the DCC, assigned a unique identification number, and then sent to the 
core cMRI Laboratory for central measurement. All echocardiograms and cMRI studies 
obtained were clinically indicated and not for the sole purpose of research.
Primary and Secondary Outcomes of Interest
The primary outcomes to be assessed as both separate and composite endpoints for the DCM 
and HCM groups included death, heart transplant or transplant listing, and worsening HF. 
Worsening HF was defined as a worsening of the New York Heart Association or Ross HF 
scores or a HF-related hospital admission. Secondary outcomes were LV mechanical 
circulatory support with a ventricular assist device or extracorporeal membrane oxygenation 
or placement of an automatic internal cardioverter defibrillator.
RESULTS
Study cohort
A total of 288 patients were enrolled. There were 506 patients screened, of whom 150 were 
ineligible. Detailed information was available to discern the reason for ineligibility in 55% 
of these. With respect to the DCM cohorts, 13 of 38 ineligible patients did not meet study 
criteria for both LV dilation and decreased function. For the HCM cohorts, 7 of 41 ineligible 
patients did not meet any of the LV posterior wall or septal thickness measurement criteria 
set forth for HCM. There were no differences between eligible patients who consented 
versus those who refused participation with respect to sex, age at diagnosis, race, or 
ethnicity (Table 4). Among screened and eligible patients, consent rate was similar between 
newly diagnosed DCM, HCM with cMRI, and chronic DCM or HCM (78%, 85%, and 81%, 
respectively).
Table 5 and Figure 2A, B and C show the actual enrollment and rate of enrollment compared 
to the target enrollment for study aim. Because of low enrollment, the OSMB required 
adjustment of the expected enrollment beginning in September of 2014. This change is 
detailed in the figures.
Actual enrollment for Aim 1 (patients with newly diagnosed DCM) was lower than expected 
based on the PCMR historical data. It also took longer than expected to accrue newly 
diagnosed DCM patients, enrolling 81% of the target sample during a 30-month time frame 
rather than the targeted 12 months. This resulted in a truncated follow-up time for this 
cohort.
The enrollment of HCM patients with a recent cMRI was lower than expected due to few 
patients undergoing cMRI during the study period.
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The number of eligible patients with chronic DCM or HCM was consistent with estimates 
from the PCMR Cohort Study data. The consent rate was also high which led to an actual 
enrollment and patient accrual time that matched the study targets.
The demographics and cardiac phenotype of the study cohort are shown in Table 6. The 
median age at diagnosis and age at enrollment for the entire cohort was 6.4 years and 11.6 
years, respectively. The median age at diagnosis for the new onset DCM was 1.7 years and 
median time from diagnosis to enrollment was 0.1 years. The median age at diagnosis for 
the HCM group with an available cMRI was 12.1 years with median time from diagnosis to 
enrollment of 0.4 years. Among children with chronic cardiomyopathy, median age at 
diagnosis was 3.4 years and median time from diagnosis to enrollment was 4.8 years. The 
majority of children enrolled were of white race (71.5%) followed by black race (12.2%), 
Asian (1.7%), American Indian/ Alaska native (1.7%), and native Hawaiian or other Pacific 
Islander (1.7%). The entire cohort includes 9.7% children of Hispanic or Latino ethnicity.
DISCUSSION
The PCM Biomarkers study is a large multisite prospective study designed to determine any 
correlation between circulating biomarkers and disease state or prognosis in children with 
DCM and HCM. The study will examine, numerous biomarkers, including those associated 
with disease severity and prognosis in adults with HF. Of these, inflammatory biomarkers, 
tumor necrosis factor and interleukin-6, (which are associated with increased mortality and 
worsening HF), 22-24, protein ST2 (or interleukin-1) which predicts death or heart transplant 
with HF, and NT-proBNP have all been well studied in adults with HF, but few data are 
available from children with primary cardiomyopathy.25,26 Some children with HCM are 
more susceptible to sudden cardiac death than others, and the factors predicting sudden 
death in adults may not necessarily be applicable to them.27 However, cardiac fibrosis is 
believed to be an important substrate for arrhythmic death in both children and adults with 
HCM.28-30 Thus, evaluating biomarkers of cardiomyocyte injury and collagen metabolism 
and correlating their concentrations with cMRI findings, echocardiographic assessments of 
LV diastolic dysfunction, and clinical outcome are potentially of great importance for 
children with HCM.
We acknowledge several challenges involved in conducting this research. First, enrolling 
children with acute DCM has proved to be more difficult than expected. To achieve 
sufficient follow up time, we anticipated an accrual period of 18 months would enroll 100 
incident cases of DCM; however, it took 30 months to enroll 81 cases. Limitations to 
enrollment included the requirement that patients have both dilation and decreased LV 
function at presentation. Several patients had decreased LV systolic function without LV 
dilation (defined as LV size more than 2 SD above normal). Moreover, the number of 
eligible patients and families who agreed to participate was also lower than expected, 
particularly for the children with newly diagnosed DCM. Investigators and coordinators 
found that the acuteness of the illness and the number of blood draws anticipated (6 total) 
hindered participation of eligible subjects. Moreover, this study did not afford any direct 
clinical benefits to the patient such as is perceived in drug trials or with other trials with an 
intervention arm. This lack of perceived benefit to the patient could have negatively 
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impacted willingness of participation by either the parents or the child, particularly when 
multiple blood draws or excess blood volume with each draw was required.
Another challenge was the stipulation that clinical visits, echocardiography, and cMRI were 
to be scheduled as clinically indicated, rather than solely for research purposes. Although the 
planned follow-up was based on standard clinical practice, variation in follow-up intervals 
occurred likely due to center and provider-specific practice, the patient’s clinical severity, or 
patient’s adherence to medical follow up. The requirement for clinically indicated cMRI 
studies in patients with HCM impacted enrollment because cMRI was obtained by many of 
the enrolling centers less often than expected during the study. This was probably related to 
the lack of published guidelines with recommendations for timing of baseline cMRI and 
frequency of serial cMRI in pediatric HCM wherein the prevalence and progression of 
cardiac fibrosis is not known. cMRI acquisition necessitates sedation for young children, 
generally less than 10 years old, so there is a hesitancy to perform sedation if the prognostic 
value of the test is not known in young children with HCM. Additionally, it was uncommon 
for clinicians to obtain a simultaneous echocardiogram and cMRI likely because it is 
unknown if there is added value in doing so. Finally, a U.S. Food and Drug Administration 
Drug Safety Alert issued after a recent report of gadolinium accumulation in the pituitary 
gland following repeated use of gadolinium-based contrast agents for MRI. Although of 
unknown relevance for children undergoing a single cMRI to assess for fibrosis, this may 
have proved an impediment to cMRI performance at some sites.31,32 All are possible reasons 
that contributed to the lower-than-expected enrollment of HCM patients with a cMRI and 
recent echocardiogram. To mitigate the under-enrollment of HCM patients with a cMRI, the 
protocol was modified from an initial requirement of a cMRI within 2-months of the 
collected biospecimen to include patients with a cMRI acquired within the past 12 months 
and an echocardiogram within 6 months. The enrollment period was also extended and 
additional participating sites were added to increase HCM enrollment. These amendments 
were feasible because the Aim 2 study objectives required a one-time only biospecimen 
sample and did not depend upon long-term follow-up data for the analysis correlating 
markers of fibrosis with cMRI or echocardiography.
Despite these limitations, we anticipate that this study will answer several important 
questions about pediatric cardiomyopathy and biomarkers.
CONCLUSIONS
The PCM Biomarkers study is determining the predictive value of serum biomarkers to aid 
in the prognosis and management of children with DCM and HCM. The results may provide 
valuable information in an area where data are currently lacking in children. We anticipate 
that this study will impact clinical practice and facilitate additional trials in pediatric 
cardiomyopathy evaluating survival and quality of life by identifying those children most at 
risk for an adverse outcome. Additionally, knowledge from study design and subject 
recruitment during the conduct of the PCM Biomarkers study will help future investigators 
design better clinical trials with appropriate enrollment goals and recruitment strategies to 
have sufficient power to assess study endpoints for pediatric HF and cardiomyopathy.
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Appendix A:
PCM Biomarkers Study Institutions
Site Principal Investigators
Wayne State University School of Medicine and Children’s Hospital of Michigan,Detroit, 
MI -Administrative Coordinating Center
Steven Lipshultz
New England Research Institutes,
Watertown, MA- Data Coordinating Center
Ling Shi, Lynn Sleeper*
The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH John Lynn Jefferies
Boston Children’s Hospital, Boston, MA Steven Colan
Children’s Hospital of Philadelphia, Philadelphia, PA Joseph Rossano
Columbia University Medical Center, New York, NY Linda Addonizio
Ann and Robert H. Lurie Children’s Hospital of Chicago and Northwestern University 
Feinberg School of Medicine, Chicago, IL
Elfriede Phal




Albert Einstein College of Medicine, Children’s Hospital at Montefiore, Bronx, NY Daphne Hsu
Primary Children’s Medical Center, Salt Lake City, UT Kimberly Molina
University of Alberta and Stollery Children’s Hospital, Edmonton, Canada Paul Kantor
St. Louis Children’s Hospital, Washington University, St. Louis, MO Charles Canter
Miller School of Medicine, University of Miami, Miami, FL Paolo Rusconi
University of Colorado and Children’s Hospital of Colorado, Aurora, CO Melanie Everitt
Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA Brian Feingold
University of Tennessee Health Science Center, St. Jude Children’s Research Hospital and 
Le Bonheur Children’s Hospital, Memphis, TN
Jeffrey Towbin
*
affiliation at the time of study design
Appendix B:
Echocardiographic Protocol: Assessment of Systolic and Diastolic 
Function
The echocardiogram included a complete two-dimensional echocardiogram and Doppler 
evaluation including a complete assessment for anatomic abnormalities, valve dysfunction 
and intracardiac thrombi, standard short and long axis views of the left ventricle to assess 
regional wall motion. The site provided age, height, weight, and blood pressure with the 
DICOM images uploaded using a commercial, HIPAA-compliant image transfer service 
(AMBRA, Inc). Images were de-identified during import to the core lab server and all 
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analyses were performed using custom software that enables archiving of all measurements 
as a non-destructive overlay and derivation of all calculated variables. All measurements 
were performed in triplicate and the average of the three measurements was used as the 
reported value. All measurements and derived variables were performed as described in the 
American Society of Echocardiography guidelines (Lopez L, Colan SD, Frommelt PS, 
Ensing GJ, Kendall K, Younoszai AK, Lai WW, Geva T. Recommendations for 
quantification methods during the performance of a pediatric echocardiogram: A report from 
the Pediatric Measurements Writing Group of the American Society of Echocardiography 
Pediatric and Congenital Heart Disease Council. J Am Soc Echocardiogr 2010; 23: 465-95). 
The measured and derived variables are listed in the table below. Body surface area was 
calculated according to the formula of Haycock et al (Haycock GB, Schwartz GJ and 
Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula 
validated in infants, children, and adults. J Pediatr 93: 62-66, 1978) and z-scores were 
obtained relative to age or BSA as previously described (Sluysmans T, Colan SD. Structural 
measurements and adjustment for growth. In: Lai WW, Cohen MS, Geva T, Mertens L, 
editors. Echocardiography in Pediatric and Congenital Heart Disease Edition 2. Wiley-
Blackwell, West Sussex, UK, 2015).
Table.
Measured and derived echocardiographic variables
Name Units Z-score
Age Years
Date of birth Date Yes
Systolic blood pressure mm Hg Yes
Diastolic blood pressure mm Hg Yes
Height cm Yes
Weight kg Yes
Body surface area m2 Yes
Isovolumic relaxation time sec Yes
Aortic root anteroposterior diastolic dimension cm Yes
Interventricular end-diastolic septal thickness cm Yes
Left ventricular posterior wall end-diastolic thickness cm Yes
Left ventricular maximal end-diastolic thickness cm Yes
Left ventricular posterior wall end-diastolic thickness cm Yes
Left ventricular end-diastolic dimension cm Yes
Left ventricular end-systolic dimension cm Yes
Left ventricular short axis end-diastolic endocardial area cm2 Yes
Left ventricular short axis end-diastolic epicardial area cm2
Left ventricular short axis end-systolic endocardial area cm2 Yes
Left ventricular long axis end-diastolic endocardial length cm Yes
Left ventricular long axis end-diastolic epicardial length cm
Left ventricular long axis end-systolic endocardial length cm Yes
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Left ventricular end-diastolic volume (5/6 × Area × Length) ml Yes
Left ventricular end-systolic volume (5/6 × Area × Length) ml Yes
Left ventricular mass (5/6 × Area × Length) gm Yes
Left atrial anteroposterior diameter cm Yes
Left atrial maximal length (apical 4-chamber view) cm Yes
Left atrial maximal area (apical 4-chamber view) cm2 Yes
Left atrial single plane volume ml Yes
Pulsed Doppler peak mitral E-wave velocity cm/sec Yes
Pulsed Doppler peak mitral A-wave velocity cm/sec Yes
Pulsed Doppler peak mitral E-wave / peak mitral A-wave none Yes
Pulsed Doppler E-wave Deceleration time msec Yes
Tissue Doppler peak e-wave velocity - lateral wall cm/sec Yes
Tissue Doppler peak a-wave velocity - lateral wall cm/sec Yes
Mitral E-wave / tissue Doppler e-wave velocity - lateral wall none Yes
Tissue Doppler peak e-wave velocity - septum cm/sec Yes
Tissue Doppler peak a-wave velocity - septum cm/sec Yes
Mitral E-wave / tissue Doppler e-wave velocity - septum none Yes
Tissue Doppler peak e wave velocity - average cm/sec Yes
Tissue Doppler peak a wave velocity - average cm/sec Yes
Mitral E-wave / tissue Doppler e-wave velocity - average none Yes
Appendix C:
MRI Protocol: Imaging Acquisition
Clinically performed cardiac MRI examinations were collected for this study. All scans were 
performed at 1.5T on conventional medical scanners with clinically approved hardware and 
software at each clinical center. The cMRI scan included: scout scans for localization; 
horizontal and vertical long- and short-axis, multiphase gated cine views using steady state 
free precession SSFP sequences for function and anatomy at the optimally highest flip angle; 
phase contrast flow quantification cine sequence acquisition above the aortic valve and 
below the aortic annulus; and late gadolinium-enhanced phase-sensitive inversion recovery 
(PSIR) gradient echo imaging performed after the administration of 0.2 mmol/Kg 
gadolinium-based MR contrast agent (gadopentetic acid (Magnevist), gadoversetamine 
(Optimark), gadodiamide (Omniscan) or gadoterate meglumine (Dotarem), (all with similar 
relaxivities), or 0.1 mmol/Kg gadobenate dimeglumine (MultiHance) (higher relaxivity), I.V. 
Late gadolinium enhancement (LGE) image was acquired at 8-10 minutes, after 
administering a gadolinium bolus using a T1-finder sequence to estimate inversion times. 
Inversion times were between 200-350 ms, set to null signal from the normal myocardium. 
All long axis images were acquired at 6 mm slice thickness. Short axis images were 
acquired at 6 mm slice thickness (0 gap) in children less than 6 years of age, and at 8 mm (0 
gap) in children 6 years of age or older. Imaging examinations were performed breathhold in 
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patients able to hold their breath. In patients unable to breathhold (ie; sedated patients or 
young children), multiaverage (3 averages) data collection was performed.
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Pediatric cardiomyopathy is a rare but clinically important disease in childhood
To date, there have been no studies in children that reliably correlate circulating 
biomarkers with outcome in children with DCM or HCM
Studies of pediatric cardiomyopathy, particularly new cases, require multi-center 
collaboration to meet enrollment needs and increase the likelihood of significant findings
Mean age of diagnosis is less than 10 years old highlights the importance of studying 
children to capture age-related factors that different from cardiomyopathy in adulthood
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Figure 1. The Biomarker Study Data Flow
The diagram shows the relationship between clinical sites and data, imaging, and 
biospecimen transfer among core labs, the DCC, and the ACC.
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Figure 2A. Rate of patient accrual for Aim 1 newly diagnosed DCM cohort was lower than 
expected. Original Expected (shown in red line), Revised Expected (shown in blue line), and 
Actual (shown in black line) rate of enrollment by newly diagnosed dilated cardiomyopathy.
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Figure 2B. Rate of patient accrual for Aim 2 hypertrophic cardiomyopathy with recent cardiac 
magnetic resonance imaging was lower than expected. Original Expected (shown in red line), 
Revised Expected (shown in blue line), and Actual (shown in black line) rate of enrollment by 
hypertrophic cardiomyopathy with recent cardiac magnetic resonance imaging.
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Figure 2C. Rate of patient accrual for Aim 3 chronic dilated and hypertrophic cardiomyopathy 
was as expected. Original Expected (shown in red line), Revised Expected (shown in blue line), 
and Actual (shown in black line) rate of enrollment of chronic dilated or hypertrophic 
cardiomyopathy.
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Table 1.
Cardiac biomarkers to be analyzed in the Cardiac Biomarkers in Pediatric Cardiomyopathy Study, by study 
aim and diagnosis













Cardiomyocyte Protein ST2 DCM DCM
Protector Growth DCM DCM
differentiation
factor 15
Beta Galactoside Galectin 3 DCM DCM
Cardiomyocyte


















TNF-alpha, tumor necrosis factor-alpha;
6
hsCRP, high-sensitivity C-reactive protein;
7




TIMP-1, tissue inhibitor of metalloproteinase-1;
10
CITP, carboxyl-terminal telopeptide of collagen type 1
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Table 2.
Inclusion Criteria for Echocardiographic and Cardiac Magnetic Resonance Imaging (MRI) Testing in the 
Cardiac Biomarkers in Pediatric Cardiomyopathy Study
Criteria Echocardiographic and/or cMRI diagnostic criteria
At least 2 qualifying measurements at diagnosis or 
enrollment
Dilated cardiomyopathy
1. LV FS or EF >2 SD below the normal mean for age
2. LV end-diastolic thickness-to-dimension ratio <0.12
3. LV end-diastolic dimension or volume >2 SD above the normal mean for body-
surface area
Any one of 3 criteria at diagnosis or enrollment Hypertrophic cardiomyopathy
1. If age <18.0 years at diagnosis: LV posterior wall or septal thickness at end-
diastole >3 SD above the normal mean for body-surface area
2. If age ≥18.0 years at diagnosis: LV posterior wall or septal thickness at end-
diastole >1.2 cm
3. Localized LV hypertrophy, such as septal thickness >1.5 × LV posterior wall 
thickness with at least normal LV posterior wall thickness
*
LV=left ventricular; FS=fractional shortening; EF=ejection fraction
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Table 3.
Exclusion Criteria in the Cardiac Biomarkers in Pediatric Cardiomyopathy Study
Age 21 years or older at time of enrollment
Heart transplant recipient
Endocrine disease known to cause heart muscle disease (including infants of mothers with diabetes)
History of rheumatic fever
Toxic exposures known to cause heart muscle disease (anthracyclines, mediastinal radiation, iron overload, or heavy metal exposure)
HIV-positive or born to an HIV-positive mother
Kawasaki disease
Congenital heart defects unassociated with malformation syndromes (e.g., valvular heart disease or congenital coronary artery malformations)
Immunologic disease
Invasive cardiothoracic procedures or major surgery during the preceding month, except those specifically related to cardiomyopathy, including 
left-ventricular assist devices, extracorporeal membrane oxygenation, and automatic internal cardiac defibrillator placement.
Active or chronic uremia
Abnormal ventricular size or function that could be attributed to intense physical training or chronic anemia
Chronic arrhythmia, unless inclusion criteria were documented before the onset of arrhythmia (not excluded were patients with chronic 
arrhythmia, subsequently successfully ablated, whose cardiomyopathy persists > 2 months post-ablation)
Malignancy
Systemic hypertension
Pulmonary parenchymal or vascular disease (e.g., cystic fibrosis, cor pulmonale, or pulmonary hypertension)
Ischemic coronary vascular disease
Association with drugs (e.g., growth hormone, corticosteroids, cocaine) or other diseases known to cause hypertrophy





■ Disorders of fatty acid metabolism
■ Friedreich ataxia
■ Glycogen storage disease (e.g. Danon, Forbes’, Pompe; PRKAG2, Forbes’, Danon)
■ Lysosomal storage diseases (e.g. Anderson–Fabry, Hurler)
■ Mitochondrial disorders
■ Noonan syndrome and related RASopathies (Noonan syndrome with multiple lentines,
 cardiofaciocutaneous syndrome, Costello syndrome)
■ Phosphorylase B kinase deficiency
■ Swyer syndrome
■ Syndromic hypertrophic cardiomyopathy
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Table 4.
Baseline Characteristics of Eligible Patients Consented versus Refused
Consented Refused P value
Total 288 68
Age at diagnosis, yr 6.4 (IQR=0.8, 12.9) 4.0 (IQR=1.0, 12.0) 0.47
Race 0.26
White 206 (71.5%) 55 (82.1%)
Black 35 (12.2%) 6 (9.0%)
Asian 5 (1.7%) 1 (1.5%)
Other 42 (14.6%) 1 (1.5%)
Ethnicity
Hispanic ethnicity 28 (9.7%) 6 (8.8%) 0.96
Gender
Male 163 (56.6%) 36 (52.9%) 0.59
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Table 5.
Summary of Target Sample Size, Eligible Patients, Consent Rate, and Actual Patient Enrollment in the Cardiac 



















New diagnosis DCM 150-180 80 18 30 103 77.7
HCM with recent cMRI 100-120 67 36 32 79 84.8
Chronic DCM or HCM 100-120 141 30 30 174 81.0
*
DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; cMRI, cardiac magnetic resonance imaging
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Table 6.













Total 80 67 141 288







Median =6.4 (IQR=0.8, 
12.9)









Time from diagnosis to 
enrollment, yr







Median =1.9 (IQR=0.1, 
5.1)
Race
White 46 (57.5%) 55 (82.1%) 105 (74.5%) 206 (71.5%)
Black 16 (20.0%) 6 (9.0%) 13 (9.2%) 35 (12.2%)
Asian 1 (1.3%) 1 (1.5%) 3 (2.1%) 5 (1.7%)
American Indian/Alaska 
Native
1 (1.3%) 1 (1.5%) 3 (2.1%) 5 (1.7%)
Native Hawaiian or Other 
Pacific Islander
4 (5.0%) 0 (0%) 1 (0.7%) 5 (1.7%)
More than one race or 
unknown
12 (15.0%) 4 (6.0%) 16 (11.4%) 32 (11.1)
Ethnicity
Hispanic or Latino 12 (15.0%) 4 (6.0%) 12 (8.5%) 28 (9.7%)
Not Hispanic or Latino 65 (81.3%) 63 (94.0%) 127 (90.1%) 255 (88.5%)
Not reported 3 (3.8%) 0 (0%) 2 (1.4%) 5 (1.7%)
Gender
Female 44 (55.0%) 15 (22.4%) 66 (46.8%) 125 (43.4%)
Male 36 (45.0%) 52 (77.6%) 75 (53.2%) 163 (56.6%)
Mean±standard deviation unless otherwise noted.
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